

## FUSIONPlex-HT Sarcoma v2

### Description

The FUSIONPlex-HT Sarcoma v2 panel is a balanced pool of gene-specific primer (GSP) oligonucleotides that is optimized for use with FUSIONPlex-HT reagents and molecular barcode (MBC) adapters to produce targeted NGS libraries. This product insert should be used in conjunction with FUSIONPlex-HT protocol for Illumina® (RA-DOC-049).

FUSIONPlex-HT Sarcoma v2 contains **659** GSPs targeting **63** genes commonly mutated in solid tumors.

Description	Part number	Storage
FUSIONPlex-HT Sarcoma v2 GSP1, 24 reactions or FUSIONPlex-HT Sarcoma v2 GSP1, 96 reactions	SA19191241 or SA19191961	-20°C ± 10°C
FUSIONPlex-HT Sarcoma v2 GSP2, 24 reactions or FUSIONPlex-HT Sarcoma v2 GSP2, 96 reactions	SA19191242 or SA19191962	
10X VCP Primer Mix, 24 reactions or 10X VCP Primer Mix, 96 reactions	SA0840 or SA0841	

### Recommended PCR cycling

	Step	Temperature (°C)	Time	Cycles
First PCR reaction	1	95	3 min	1
	2	95	30 sec	15
	3	60	10 sec	
	4	63	5 min (100% ramp rate)	
	5	72	3 min	1
	6	4	Hold	1

## Recommended PCR cycling (*cont.*)

	Step	Temperature (°C)	Time	Cycles
Second PCR reaction	1	95	3 min	1
	2	95	30 sec	
	3	60	10 sec	20†
	4	65	5 min (100% ramp rate)	
	5	72	3 min	1
	6	4	Hold	1

†The number of PCR2 cycles may be decreased if you regularly experience library yields greater than 200 nM.

## Recommended reads and multiplexing

FUSIONPlex-HT Sarcoma v2 libraries should be sequenced to a minimum of **2M** reads. Starting read depth recommendations for standard profiling may be adjusted based on user needs.

## Archer™ Analysis settings

Sequencing data should be processed using Archer Analysis (v7, or greater). The FUSIONPlex-HT Sarcoma v2 panel requires selection of the FUSION pipeline and (optional) **SNV/Indel** pipeline, found under the **RNA** Input Type. See the Archer Analysis User Guide for more details on setting up your analysis.

Processing of FUSIONPlex-HT Sarcoma v2 libraries requires a one-time upload of the Custom Panel GTF. Files can be obtained by contacting [archer-tech@idtdna.com](mailto:archer-tech@idtdna.com).

## Assay targets

Gene	Accession	Exon	Variant Type	Description**
ALK	NM_004304	2, 4, 6, 8, 10, 12, 14, 16, 17, 18, 19, intron19, 20, mid-exon20, 21, 22, 23, 26	Fusion, ALK ATIV, Internal deletion (ALKΔ2-17, ALKΔ2-3)	5'
ALK	NM_004304	1, 2	Internal deletion (ALKΔ2-17, ALKΔ2-3)	3'
ALK	NM_004304	22, 23, 25	Mutation	p.P1153-p.C1156,p.F1174,p.L1196-p.S1206,p.G1269

Gene	Accession	Exon	Variant Type	Description**
<i>BCOR</i>	NM_017745	8	Fusion	5'
<i>BCOR</i>	NM_001123385	mid-exon2, 3, 4, mid-exon4, 5, 6, 7, 8, 9, 11, 15	Fusion, Internal Tandem Duplication	5'
<i>BCOR</i>	NM_001123385	2, 4, mid-exon4, 6, 7, mid-exon7, 10, 12, 14, 15	Fusion, Internal Tandem Duplication	3'
<i>BRAF</i>	NM_004333	2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 15, 16	Fusion, Kinase Domain Duplication, BRAFΔ2-10, BRAFΔ4-10, BRAFΔ2-8, BRAFΔ3-8, BRAFΔ4-8	5'
<i>BRAF</i>	NM_004333	1, 2, 3, 7, 8, 10, 13, 14, 18	Fusion, Kinase Domain Duplication, BRAFΔ2-10, BRAFΔ4-10, BRAFΔ2-8, BRAFΔ3-8, BRAFΔ4-8	3'
<i>BRAF</i>	NM_004333	15	Mutation	p.V600
<i>CAMTA1</i>	NM_015215	8, 9, mid-exon9, 10	Fusion	5'
<i>CAMTA1</i>	NM_015215	3	Fusion	3'
<i>CCNB3</i>	NM_033031	2*, 3, 4, 5, 6, mid-exon 6, 7	Fusion	5'
<i>CIC</i>	NM_015125	12	Fusion	5'
<i>CIC</i>	NM_015125	14, 15, 16, 17, 18, mid-exon19, 19, mid-exon20, 20*	Fusion	3'
<i>CSF1</i>	NM_000757	2, 3, 4, 5, 6	Fusion	5'
<i>CSF1</i>	NM_000757	5, 6, 7, 8*, mid-exon9*	Fusion	3'
<i>CSF1</i>	NM_172212	9*	Fusion	3'
<i>CTNNB1</i>	NM_001904	3	Mutation	p.D32-p.S37
<i>EGFR</i>	NM_005228	7, 8, 9, 14, 15, 16, 17, 18, 19, 20	Fusion, Exon 2-7 Skipping (EGFRvIII), Kinase Domain Duplication	5'

Gene	Accession	Exon	Variant Type	Description**
<i>EGFR</i>	NM_005228	1, 24, 25, mid-exon25, 26	Fusion, Exon 2-7 Skipping (EGFRvIII), Kinase Domain Duplication	3'
<i>EGFR</i>	NM_005228	18, 19, 20, 21	Mutation	p.E709-p.G719,p.E746-p.L760,p.V774-p.G796,p.L858-p.L861
<i>EPC1</i>	NM_025209	9, 10, 11	Fusion	3'
<i>ERG</i>	NM_004449	2*, 3*, 4, 5, 6, 7, 8, 9, 10, 11	Fusion	5'
<i>ESR1</i>	NM_000125	5, 6, 7, 8	Fusion	5'
<i>ESR1</i>	NM_000125	1, 2, 3, 4, 5, 6, 7	Fusion	3'
<i>ETV1</i>	NM_004956	3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13	Fusion	5'
<i>ETV4</i>	NM_001986	2, 3, 4, 5, 6, 7, 8, 9, 10	Fusion	5'
<i>ETV5</i>	NM_004454	2*, 3, 7, 8, 9	Fusion	5'
<i>ETV6</i>	NM_001987	2, 3, 4, 5, 6, 7	Fusion	5'
<i>ETV6</i>	NM_001987	1, 2, 3, 4, 5, 6	Fusion	3'
<i>ETV6</i>	NM_001987	3	Mutation	p.Y104-p.R105
<i>EWSR1</i>	NM_005243	8	Fusion	5'
<i>EWSR1</i>	NM_005243	4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14	Fusion	3'
<i>FGFR1</i>	NM_015850	2*, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17	Fusion, Kinase Domain Duplication	5'
<i>FGFR1</i>	NM_015850	12, 17	Fusion, Kinase Domain Duplication	3'
<i>FGFR1</i>	NM_023110	4, 13, 14	Mutation	p.T141,p.V561,p.K656
<i>FGFR2</i>	NM_000141	2*, 3, 5, 6, 7, 8, 9, 10	Fusion	5'

Gene	Accession	Exon	Variant Type	Description**
<i>FGFR2</i>	NM_000141	16, 17, 18	Fusion	3'
<i>FGFR2</i>	NM_000141	7, 9, 12, 13, 14	Mutation	p.S252-p.P253,p.G305,p.Y375-V395,p.I547-p.N549,p.V564,p.A648-p.K659
<i>FGFR3</i>	NM_000142	3, 5, 8, 9, 10, 11, 12, 13, 14	Fusion	5'
<i>FGFR3</i>	NM_000142	16, 17, intron17, mid-exon18	Fusion	3'
<i>FGFR3</i>	NM_000142	7, 9, 13, 14, 16	Mutation	p.R248-p.S249,p.G370-p.R399,p.V555,p.D641-p.K650,p.G697-p.K715
<i>FOS</i>	NM_005252	mid-exon4	Fusion	3'
<i>FOSB</i>	NM_006732	1*, mid-exon1*, 1, 2	Fusion	5'
<i>FOXO1</i>	NM_002015	1*, 2, 3*	Fusion	5'
<i>FOXO1</i>	NM_002015	1*, 2*, 3*	Fusion	3'
<i>FUS</i>	NM_004960	3, 4, 5, mid-exon6, 6, 7, 8, 9, 10, 11, 13, 14	Fusion	3'
<i>GLI1</i>	NM_005269	4, 5, 6, 7	Fusion	5'
<i>GLI1</i>	NM_005269	4, 5, mid-exon5, 6, 7	Fusion	3'
<i>HMGA2</i>	NM_003483	1, 2, 3, 4, mid-exon5*, 5*	Fusion	3'
<i>JAZF1</i>	NM_175061	2, 3, 4	Fusion	3'
<i>MBTD1</i>	NM_017643	3*	Fusion	5'
<i>MBTD1</i>	NM_017643	15, 16, 17	Fusion	3'
<i>MDM2</i>	NM_002392	5, 9	Fusion, Expression	5'
<i>MDM2</i>	NM_002392	2, 4, 6, 8, 10	Fusion, Expression	3'

Gene	Accession	Exon	Variant Type	Description**
<i>MEAF6</i>	NM_001270875	4, 5	Fusion	3'
<i>MET</i>	NM_000245	2, 4, 5, 6, 13, 14, 15, 16, 17, 21	Fusion, Exon 14 Skipping (METΔex14)	5'
<i>MET</i>	NM_000245	2, 13	Fusion, Exon 14 Skipping (METΔex14)	3'
<i>MGEA5</i>	NM_012215	4, 5, 6, 7, 8, 9, 12, 13, 14, 15	Fusion, Expression	5'
<i>MKL2</i>	NM_014048	11, 12, 13	Fusion	5'
<i>MYOD1</i>	NM_002478	1	Mutation	p.L122, full CDS coverage for mutation detection
<i>NCOA1</i>	NM_147223	11, 12, 13, 14, 15	Fusion	5'
<i>NCOA2</i>	NM_006540	11, 12, 13, 14, intron14, 15, 16, 22	Fusion	5'
<i>NCOA2</i>	NM_006540	14	Fusion	3'
<i>NCOA3</i>	NM_006534	2*, 13, 14, 15, 16	Fusion	5'
<i>NCOA3</i>	NM_006534	20	Fusion	3'
<i>NR4A3</i>	NM_173200	2*, 3*, 4, 5, 7, 9	Fusion, Expression	5'
<i>NR4A3</i>	NM_173200	8	Fusion, Expression	3'
<i>NTRK1</i>	NM_001007792	1, 2	Fusion	5'
<i>NTRK1</i>	NM_002529	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14	Fusion	5'
<i>NTRK1</i>	NM_002529	13, 14, 15, 16, 17	Mutation	Full Kinase Domain coverage for resistance mutations including p.G595
<i>NTRK2</i>	NM_006180	4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18	Fusion	5'
<i>NTRK2</i>	NM_006180	11, 14	Fusion	3'

Gene	Accession	Exon	Variant Type	Description**
<i>NTRK2</i>	NM_006180	16, 17, 18, 19, 20, 21	Mutation	Full Kinase Domain coverage for resistance mutations
<i>NTRK3</i>	NM_001007156	15	Fusion	5'
<i>NTRK3</i>	NM_002530	3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16	Fusion	5'
<i>NTRK3</i>	NM_002530	13, 14, 15, 17	Fusion	3'
<i>NTRK3</i>	NM_002530	15, 16, 17, 18, 19	Mutation	Full Kinase Domain coverage for resistance mutation detection including p.F617,p.G623,p.G696
<i>NUTM1</i>	NM_175741	2*, 3, mid-exon3, 4, 5, mid-exon6, 6	Fusion	5'
<i>PAX3</i>	NM_181459	2, 4, 8	Fusion, Expression	5'
<i>PAX3</i>	NM_181459	3, 5, 6, 7, 8	Fusion, Expression	3'
<i>PDGFB</i>	NM_002608	2, 3	Fusion	5'
<i>PDGFRA</i>	NM_006206	10, 11, 12, mid-exon12, 13, 14, 15	Fusion,PDGFRAΔ8,9	5'
<i>PDGFRA</i>	NM_006206	7	Fusion,PDGFRAΔ8,9	3'
<i>PDGFRA</i>	NM_006206	15, 18	Mutation	p.T674,p.D842
<i>PHF1</i>	NM_024165	1*, 2	Fusion	5'
<i>PHF1</i>	NM_024165	10, 11, 12	Fusion	3'
<i>PLAG1</i>	NM_002655	1, 2, 3, 4	Fusion	5'
<i>PRKCA</i>	NM_002737	4, 5, 6, 9, 15	Fusion	5'
<i>PRKCB</i>	NM_002738	1, 3, 7, 8, 9	Fusion	5'
<i>PRKCD</i>	NM_006254	9, 10, 11, 12, 15	Fusion	5'

Gene	Accession	Exon	Variant Type	Description**
<i>PRKCD</i>	NM_006254	18	Fusion	3'
<i>RAF1</i>	NM_002880	2*, 4, 5, 6, 7, 8, 9, 10, 11, 12	Fusion	5'
<i>RAF1</i>	NM_002880	4, 5, 6, 7, 8, 9	Fusion	3'
<i>RET</i>	NM_020630	2, 4, 6, 8, 9, 10, 11, mid-exon11, 12, 13, 14	Fusion	5'
<i>RET</i>	NM_020630	15, 16	Mutation	p.A883,p.M918
<i>ROS1</i>	NM_002944	2, 4, 7, 31, 32, 33, 34, 35, 36, 37	Fusion	5'
<i>ROS1</i>	NM_002944	38	Mutation	p.G2032
<i>SS18</i>	NM_001007559	2, 3, 4, 5, 6, 10, 11	Fusion	5'
<i>SS18</i>	NM_001007559	4, 5, 6, 8, 9, 10	Fusion	3'
<i>STAT6</i>	NM_001178078	1*, 2*, 3, 4, 5, 6, 7, 15, 16, 17, 18, 19, 20	Fusion	5'
<i>TAF15</i>	NM_139215	6, 7	Fusion	5'
<i>TAF15</i>	NM_139215	5, 6, 7, 9	Fusion	3'
<i>TCF12</i>	NM_207036	4, 5, 6	Fusion	3'
<i>TFE3</i>	NM_006521	2, 3, 4, 5, 6, 7, 8	Fusion	5'
<i>TFE3</i>	NM_006521	2, 3, 4, 5, 6	Fusion	3'
<i>TFG</i>	NM_006070	6	Fusion	5'
<i>TFG</i>	NM_006070	3, 4, 5, 6, 7, mid-exon8	Fusion	3'
<i>USP6</i>	NM_004505	1*, mid-exon1*, 2*, 3	Fusion	5'
<i>VGLL2</i>	NM_182645	1, 2, 3, intron3, 4	Fusion	3'



Gene	Accession	Exon	Variant Type	Description**
YAP1	NM_001130145	1, mid-exon1, 2, 3, 4, 8, 9	Fusion	5'
YAP1	NM_001130145	1, 2, 3, 4, 5, 6, 7	Fusion	3'
YWHAE	NM_006761	5	Fusion	3'

\*Indicates exons that are entirely untranslated region (UTR), or for which the UTR is targeted.

\*\*The mutations listed under the Description column are targeted by the assay design. Version 6.2 and earlier of Archer Analysis may not support RNA SNV/Indel variant calling at exon junctions depending on the sequence context (SNVs ≤5bp, indels ≤30bp). *De Novo* RNA SNV/Indel and Internal Tandem Duplication mutation detection are not supported on the Ion Torrent Sequencing System.

∇ALK-ATI currently requires review outside of Archer Analysis.

## Limitations of use

**For research use only. Not for use in diagnostic procedures.** Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

Safety data sheets pertaining to this product are available upon request.

This product or service is licensed under one or more of the following U.S. Patents: 8,835,358; 9,290,808; 9,290,809; 9,315,857; 9,708,659; and 9,816,137 owned by BD and is licensed solely for the use described in the associated product literature. No other rights, implied or otherwise, are granted to purchaser hereunder. Purchaser agrees, by way of example and not limitation, not to use this product to trace back the origin of a nucleic acid to an individual cell as a discrete entity (e.g., single cell analysis).

© 2023 Integrated DNA Technologies, Inc. All rights reserved. FUSIONPlex, VARIANTPlex, LIQUIDPlex, IMMUNOVERSE, Archer Analysis, and Archer Assay Marketplace are trademarks of Integrated DNA Technologies, Inc. All other marks are the property of their respective owners. For specific trademark and licensing information, see [www.idtdna.com/trademarks](http://www.idtdna.com/trademarks).

## Revision History

Document Number	Date	Description of change
<i>RA-DOC-455/REV01</i>	October 2023	Initial release
<i>RA-DOC-455/REV02</i>	November 2023	Updated First and Second PCR cycling conditions to include separate anneal and extended steps.  Updated branding.